Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Rastogi

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
Springerplus|April 22, 2016
Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory studyTheresa A Koleck, Catherine M Bender, Susan M Sereika, et al.
Menopause (New York, N.Y.)|September 28, 2007
Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancerCatherine M Bender, Susan M Sereika, Adam M Brufsky, et al.
Bone|March 29, 2016
Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trialChaithra Prasad, Susan L Greenspan, Karen T Vujevich, et al.
Breast Cancer (Dove Medical Press)|April 21, 2017
An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivorsTheresa A Koleck, Catherine M Bender, Beth Z Clark, et al.
NPJ Breast Cancer|November 21, 2018
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancerCharles E Geyer, Gong Tang, Eleftherios P Mamounas, et al.
Breast Cancer Research and Treatment|August 21, 2019
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combinationSandra M Swain, Gong Tang, Peter C Lucas, et al.
NPJ Breast Cancer|May 14, 2026
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41Ilana Schlam, Gong Tang, Khalid AbdulJabbar, et al.
Breast Cancer Research and Treatment|October 13, 2019
A pooled analysis of the cardiac events in the trastuzumab adjuvant trialsEvandro de Azambuja, Noam Ponde, Marion Procter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2020
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete ResponseSandra M Swain, Gong Tang, Heather Ann Brauer, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 8, 2015
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38Reena S Cecchini, Sandra M Swain, Joseph P Costantino, et al.
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Springerplus|April 22, 2016
Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory studyTheresa A Koleck, Catherine M Bender, Susan M Sereika, et al.
Menopause (New York, N.Y.)|September 28, 2007
Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancerCatherine M Bender, Susan M Sereika, Adam M Brufsky, et al.
Bone|March 29, 2016
Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trialChaithra Prasad, Susan L Greenspan, Karen T Vujevich, et al.
Breast Cancer (Dove Medical Press)|April 21, 2017
An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivorsTheresa A Koleck, Catherine M Bender, Beth Z Clark, et al.
NPJ Breast Cancer|November 21, 2018
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancerCharles E Geyer, Gong Tang, Eleftherios P Mamounas, et al.
Breast Cancer Research and Treatment|August 21, 2019
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combinationSandra M Swain, Gong Tang, Peter C Lucas, et al.
NPJ Breast Cancer|May 14, 2026
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41Ilana Schlam, Gong Tang, Khalid AbdulJabbar, et al.
Breast Cancer Research and Treatment|October 13, 2019
A pooled analysis of the cardiac events in the trastuzumab adjuvant trialsEvandro de Azambuja, Noam Ponde, Marion Procter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2020
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete ResponseSandra M Swain, Gong Tang, Heather Ann Brauer, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 8, 2015
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38Reena S Cecchini, Sandra M Swain, Joseph P Costantino, et al.
Pageof 9